Genentech Biooncology
Genentech Biooncology
    • Home 

    • Research Education 

    • Research VEGF 

    • Why is the VEGF ligand essential throughout tumor development? 

    • The VEGF ligand and angiogenesis 

    • Role of Genentech BioOncology in VEGF research 

    • GLOSSARY
    • ON
    • OFF
  • Print
  • share
 
 
' The related resources bookmark allows you to jump directly to other pages on the site that contain information directly related to the topics you're currently exploring.
  • Home Page
  • What's New?
  • Tumor Types
  • Molecular Causes of Cancer
  • Biological Pathways
  • Therapeutic Targets
  • Pipeline Molecules
  • Research Education
    • Research ADCs
    • Research Apoptosis
    • Research B cell
    • Research BRAF
    • Research Cancer Immunotherapy
    • Research HDIs
    • Research HER Pathways
    • Research MET
    • Research VEGF
      • Why is the VEGF ligand essential throughout tumor development?
        • The VEGF ligand and angiogenesis
          • Angiogenesis is essential to tumor development
          • The angiogenic process
          • VEGF: a predominant mediator of angiogenesis
          • History of VEGF and angiogenesis research
          • Landmark papers
          • Role of Genentech BioOncology in VEGF research
      • What are the strategies for inhibiting the VEGF pathway?
      • What are the effects of direct VEGF ligand inhibition?
      • Why is continued VEGF inhibition important?
      • Why do tumors progress?
      • The role of VEGF across tumor types
      • Slide decks and videos
      • Glossary
  • Clinical Trials
  • Resources
  • Contact Us
Register for Updates Unsubscribe Share
Register for Updates Unsubscribe Share

Related Resources for this page:

  • Tumor Types
    • Colorectal Cancer
    • Glioblastoma
    • Lung Cancer
    • Ovarian Cancer
    • Pancreatic Cancer
    • Renal Cell Carcinoma
  • Molecular Causes of Cancer
    • Evading growth suppressors
    • Inducing angiogenesis
    • Activating invasion and metastasis
  • Biological Pathways
    • Angiogenic Signaling
    • Apoptosis
    • B-cell Surface Proteins
    • HER Signaling
    • MAPK Signaling
    • PI3K/Akt/mTOR Signaling
  • Therapeutic Targets
    • Bcl-2
    • HER1
    • HER2
    • HER3
    • HER4
    • VEGF
  • Clinical Trials
    • Colorectal Cancer
    • Lung Cancer
  • Cancer Biomarkers
    • Colorectal Cancer
      • Oncogenic BRAF and prognosis
      • Oncogenic BRAF in cancer
    • Lung Cancer
      • Receptor-Mediated Endocytosis
      • Cytotoxic agent
      • What are ADCs?
      • Stable linker
      • Monoclonal antibody
      • Current research in ADCs
      • Targeting cancers with ADCs
      • Glossary
      • A brief history of ADCs
      • How are ADCs designed to work?
      • Research ADCs
      • Multimedia Resources
  • Future Directions
    • Antibody-Drug conjugates
      • HER Signaling
      • Receptor-Mediated Endocytosis
      • Anti-HER3/EGFR MAb (MEHD7945A)
      • Anti-PDL1 (MPDL3280A)
      • Cytotoxic agent
      • What are ADCs?
      • Stable linker
      • Monoclonal antibody
      • Current research in ADCs
      • Targeting cancers with ADCs
      • Glossary
      • A brief history of ADCs
      • How are ADCs designed to work?
      • Research ADCs
      • Multimedia Resources
    • Glycoengineered Antibodies
      • HER Signaling
      • Anti-HER3/EGFR MAb (MEHD7945A)
    • Non-Antibody Biologics
      • Apoptosis
    • Targeted Small Molecules
      • Apoptosis
      • MAPK Signaling
      • PI3K/Akt/mTOR Signaling
      • Anti-HER3/EGFR MAb (MEHD7945A)
      • Glossary
      • Resisting apoptosis
    • Traditional Monoclonal Antibodies
      • Angiogenic Signaling
      • B-cell Surface Proteins
      • HER Signaling
      • Parsatuzumab (Anti-EGFL7)
      • Anti-HER3/EGFR MAb (MEHD7945A)
      • Anti-PDL1 (MPDL3280A)

Video

Full VEGF & angiogenesis

View video now

Slides

Science of VEGF and angiogenesis

View Slides

Links

  • A specific approach to VEGF inhibition
  • The need for continuous VEGF inhibition
  • The role of VEGF across tumor types
Share

The role of Genentech BioOncology in VEGF research

For over 2 decades, researchers at Genentech BioOncology led by Napoleone Ferrara have contributed to research in VEGF and angiogenesis. This journey of discovery was facilitated by a culture of both science and creativity at Genentech, where scientists are encouraged to spend a portion of their time on their own research interests. So, while Ferrara was originally hired to study the reproductive system, his interest in angiogenesis was allowed to flourish, leading to important discoveries in this new and exciting field.

Identification and isolation of VEGF

Hypothesizing that mitogenic effect observed with endothelial cells (in a medium conditioned by bovine pituitary cells) was mediated by a secreted protein, Genentech researchers become the first to identify and isolate a new pro-angiogenic factor. Because the protein promotes the growth of only vascular endothelial cells, it is named vascular endothelial growth factor (VEGF).1

Purification and cloning of VEGF

Genentech researchers identify cDNA clones encoding 121-, 165-, and 189-amino acid molecular species of VEGF. The classical secretory signal sequence observed in these clones confirms that VEGF is, in fact, a secreted protein.2

Elucidation of the first VEGF receptor

Working with scientists from the University of California at San Francisco, Genentech researchers demonstrate that a receptor on the surface of endothelial cells (FLT1) is a high-affinity receptor for VEGF.3

Characterization of the role of VEGF in physiologic angiogenesis

Having already contributed to the growing evidence implicating VEGF in tumor angiogenesis, Genentech researchers collaborate to show that VEGF is also required for embryonic vasculogenesis.4

In the years since these important discoveries, Genentech BioOncology has maintained an ongoing commitment to basic research in this field and continues to explore the role of VEGF in many solid tumors.

References:
1.
Ferrara N, Henzel WJ. Biochem Biophys Res Commun. 1989;161:851-858. PMID: 2735925
2.
Leung DW, Cachianes G, Kuang WJ, et al. Science. 1989;246:1306-1309. PMID: 2479986
3.
Autiero M, Waltenberger J, Communi D, et al. Nat Med. 2003;9:936-943. PMID: 12796773
4.
Ferrara N, Carver-Moore K, Chen H, et al. Nature. 1996;380:439-442. PMID: 8602242
 
  • SITEMAP
  • /
  • PRIVACY POLICY
  • /
  • TERMS & CONDITIONS
  • /
  • CONTACT US
  • /
  • © 2013 Genentech USA, Inc. All rights reserved.
  • /
  • BIO0000907901
Next section: What are the strategies for inhibiting the VEGF pathway? »

© 2011 Genentech USA, Inc. All rights reserved